| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
In this study towards development of more effective natural killer (NK) cell therapy against cancer and leukemia, we investigated on the genetic determinants that can predict individuals’ NK cell functions. In healthy adults, we observed significant association of NKG2D haplotypes with NK cell functions. We also observed association of KIR haplotypes with in-vitro cytokine/chemokine production. In addition, we found that donor KIR haplotypes significantly affected the clinical outcomes such as acute GVHD after allogeneic hematopoietic stem cell transplantations. In addition to the abovementioned studies, we investigated on a novel method to transfer chimeric antigen receptor into human primary NK cells by using trogocytosis phenomenon to confer them capability to kill malignant cells in an antigen-specific manner. Expression by using trogocytosis was possible, but expression levels were not enough for clinical translation and will require further modification and improvement.
|
